clinical trial · NCT00571389
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
BioCytics, Inc.·—·recruiting·n = 1,500
Solid Tumor, AdultHealthy DonorsCOVID-19 Donors
brief summary
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells.
started
Nov 1, 2007
primary completion
Feb 1, 2030
completion
Feb 1, 2030
last updated
Mar 18, 2026
official title
A Biospecimen Collection Study to Facilitate Development of an Ex-Vivo Device Platform for Culture, Immune Assay, and Biobanking of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol